- Home
- ICLR vs BXP Comparison
ICLR vs BXP Comparison
Compare ICLR & BXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICLR | BXP |
|---|---|---|
| Founded | 1990 | 1970 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 11.1B |
| IPO Year | 2001 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ICLR | BXP |
|---|---|---|
| Price | $167.95 | $66.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 18 |
| Target Price | ★ $178.62 | $71.94 |
| AVG Volume (30 Days) | 955.3K | ★ 1.4M |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.86% |
| EPS Growth | N/A | ★ 1833.33 |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | ★ $3,482,279,000.00 |
| Revenue This Year | N/A | $11.00 |
| Revenue Next Year | N/A | $2.91 |
| P/E Ratio | ★ $12.91 | $104.59 |
| Revenue Growth | N/A | ★ 2.19 |
| 52 Week Low | $66.57 | $49.93 |
| 52 Week High | $211.00 | $79.33 |
Technical Indicators
Market Signals| Indicator | ICLR | BXP |
|---|---|---|
| Relative Strength Index (RSI) | 64.46 | 55.94 |
| Support Level | $154.56 | $65.16 |
| Resistance Level | $193.87 | $67.10 |
| Average True Range (ATR) | 7.49 | 1.52 |
| MACD | -0.56 | -0.18 |
| Stochastic Oscillator | 68.87 | 48.36 |
Price Performance
Historical ComparisonAbout ICLR ICON plc
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
About BXP Boston Properties Inc.
BXP owns 179 properties consisting of approximately 52.6 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.